Shandong Xinhua Pharmaceutical (HKG:0719) received the registration certificate for its bisoprolol fumarate tablets from China's National Medical Products Administration, a Monday Hong Kong bourse filing said.
The drug is indicated for the treatment of hypertension, coronary heart disease, and chronic stable heart failure accompanied by decreased left ventricular systolic function.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.